Analysis of the differences between the efficacy, price and original drug of Laos Lucius version of adagrasib (Krazati)

Adagrasib (trade name: Krazati) is a KRAS G12C inhibitor developed by Mirati Therapeutics and has a similar mechanism of action to sotorasib. The drug irreversibly binds to the KRAS G12C mutant protein, thereby blocking signal transduction and inhibiting tumor cell growth. In clinical trials, adagrasib has shown good efficacy in patients with non-small cell lung cancer (NSCLC) and colorectal cancer KRAS G12C mutations, and some research results show that its objective response rate is 40% It has a certain disease control rate and lasting response time.

Currently, adagrasib has been approved for marketing by FDA in the United States, but has not yet been approved in mainland China, so domestic patients can only obtain it through overseas channels. American original research version Krazati The drug price is very high, with the price of each box being about hundreds of thousands of yuan, which is a huge financial burden for most patients and is not conducive to long-term use. Because of this, many patients will focus on overseas generic drugs that are more affordable.

In overseas channels, the generic drug of Lucius version of adagrasibu produced in Laos has received widespread attention. The ingredients of this version of the drug are basically the same as those of the original drug in the United States. It is produced strictly in accordance with the standards of generic drugs. Each box sells for about more than 3,000 yuan. Compared with the original drug, the price gap is huge. Because its ingredients and efficacy are theoretically equivalent, patients can also obtain relatively close clinical effects during treatment, so it is used as an alternative choice by many patients with limited economic conditions.

Overall, adagrasib has clear clinical value as a KRAS G12C target drug. However, the price of the original drug is too high, which limits accessibility. In contrast, the price of the Laos Lucius version of the generic drug is only a fraction of the original drug, significantly reducing the cost of medication. If patients can obtain generic drugs through formal and reliable channels, their clinical efficacy can basically meet their treatment needs. However, in the long term, once the drug is approved in China and entered into medical insurance, the safety and accessibility of drugs through formal channels will be more guaranteed.

Reference link:https://www.drugs.com